Research output per year
Research output per year
Personal profile
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Fingerprint
Dive into the research topics where Jeroen Hiltermann is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Baseline Blood CD8+ T Cell Activation Potency Discriminates Responders from Non-Responders to Immune Checkpoint Inhibition Combined with Stereotactic Radiotherapy in Non-Small-Cell Lung Cancer
Kievit, H., Muntinghe-Wagenaar, M. B., Abdulahad, W. H., Rutgers, A., Hijmering-Kappelle, L. B. M., Hiddinga, B. I., Ubbels, J. F., Wijsman, R., van der Leij, M. J., Bijzet, J., Groen, H. J. M., Kerstjens, H. A. M., van der Wekken, A. J., Kroesen, B.-J. & Hiltermann, T. J. N., 19-Jul-2024, In: Cancers. 16, 14, 12 p., 2592.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile10 Downloads (Pure) -
Blood platelet RNA profiles do not enable for nivolumab response prediction at baseline in patients with non-small cell lung cancer
Muller, M., Best, M. G., van der Noort, V., Hiltermann, T. J. N., Niemeijer, A.-L. N., Post, E., Sol, N., In 't Veld, S. G. J. G., Nogarede, T., Visser, L., Schouten, R. D., van den Broek, D., Hummelink, K., Monkhorst, K., de Langen, A. J., Schuuring, E., Smit, E. F., Groen, H. J. M., Wurdinger, T. & van den Heuvel, M. M., 19-Mar-2024, In: Tumor Biology. 46, 1, p. S327-S340 14 p.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile2 Citations (Scopus)8 Downloads (Pure) -
Clinical outcomes with perioperative nivolumab (NIVO) by nodal status among patients (pts) with stage III resectable NSCLC: Results from the phase 3 CheckMate 77T study
Provencio, M., Awad, M. M., Spicer, J., Janssens, A., Moiseenko, F. V., Gao, Y., Watanabe, Y., Alexandru, A., Guisier, F., Frost, N., Franke, F. A., Hiltermann, T. J. N., He, J., Tanaka, F., Lu, S., Erdmann, C. C., Sathyanarayana, P., Tran, P., Devas, V. & Cascone, T., 5-Jun-2024, In: Journal of Clinical Oncology. 42, 17_suppl, LBA8007.Research output: Contribution to journal › Meeting Abstract › Academic
-
Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement
Vermeulen, O. C. B., Brouwer, E., Slart, R. H. J. A., Sandovici, M., Rutgers, A., Hilterman, T. J., Hiddinga, B., Oosting, S. F., Jalving, M., de Heij, A. H., Knapen, D. G., Hospers, G. A. P. & van der Geest, K. S. M., 9-Feb-2024, (E-pub ahead of print) In: Rheumatology (Oxford, England). 9 p., keae099.Research output: Contribution to journal › Erratum
Open AccessFile17 Downloads (Pure) -
The association of nutritional and inflammatory biomarkers with overall survival in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors
Horstman, I. M., Vinke, P. C., Suazo-Zepeda, E., Hiltermann, T. J. N., Heuvelmans, M. A., Corpeleijn, E. & de Bock, G. H., Aug-2024, In: Thoracic Cancer. 15, 23, p. 1764-1771 8 p.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile1 Citation (Scopus)7 Downloads (Pure)
Activities
-
Efficacy and Safety of Rilvegostomig, an Anti-PD-1/TIGIT Bispecific, for CPI-naïve Metastatic NSCLC with PD-L1 1-49% or ≥50%
Hiltermann, J. (Invited speaker)
9-Sept-2024Activity: Talk and presentation › Academic presentation › Academic
File -
NY ESO, Investigator Meeting GSK
Hiltermann, J. (Attendee)
16-Jan-2020 → 17-Jan-2020Activity: Organising and attending an event › Attending an event › Professional
-
SON NVALT
Hiltermann, J. (Attendee)
18-Jan-2020Activity: Organising and attending an event › Attending an event › Professional
-
Immunotherapie bij NSCLC
Hiltermann, J. (Invited speaker)
16-Jan-2020Activity: Talk and presentation › Professional or public presentation › Professional
-
Immunotherapie beschikbaar voor de perifere longarts? De visie van een longarts
Hiltermann, J. (Invited speaker)
12-Sept-2019Activity: Talk and presentation › Professional or public presentation › Professional
Press/Media
-
Terminaal zieke John Franke strijdt met podcast voor bevolkingsonderzoek naar longkanker
01/08/2022
1 Media contribution
Press/Media: Expert Comment › Popular
-
-
EERSTE LONGKANKERPATIËNT BEHANDELD MET GEMODIFICEERDE T-CELLEN Primeur met TCR T-cellen
04/10/2021
2 items of Media coverage
Press/Media: Expert Comment › Popular